Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals (MXC) has been granted a patent from the Slovenian Intellectual Property Office (SIPO) for CimetrA
- The patent provides MGC with commercial protection over the intellectual property regarding the formation and manufacturing process of CimetrA for a 20-year period
- CimetrA is MGC’s natural, immune-modulation formula that is made up of vitamin C and herbal extracts used to treat anti-inflammatory illnesses
- MGC Pharma enters Friday trade with shares trading at 2.2 cents
MGC Pharmaceuticals (MXC) has been granted a patent from the Slovenian Intellectual Property Office (SIPO) for CimetrA.
The patent provides MGC Pharma with commercial protection over the intellectual property regarding the formation and manufacturing process of CimetrA for a 20-year period.
CimetrA is made up of artemisinin, a drug from a fern-like plant that is used against malaria, and curcumin, a chemical that aids in anti-inflammatory and antioxidants.
It is then mixed with vitamin C and boswellia serrata, a herbal extract used to treat inflammatory illnesses.
It can come in either a solid or a liquid form and has antioxidant, anti-inflammatory and immuno-modulating properties.
“The grant of the patent by the Slovenian Intellectual Property Office is a key milestone for MGC Pharma, with the patent acknowledging the uniqueness of CimetrA’s formulation, as well as providing commercial protection of the intellectual property used to manufacture the product,” Co-Founder and Managing Director Roby Zomer said.
“The grant of the patent is a further step forward for MGC Pharma in its strategy to the development of a range of proprietary products, and becoming a wholly bio-pharma company with the ability to produce high-grade pharmaceutical products to the treat the symptoms of some of the most debilitating conditions.”
MGC Pharma enters Friday trade with shares trading at 2.2 cents.
